CIS-DICHLORODIAMMINEPLATINUM(II) AND DTIC IN MALIGNANT-MELANOMA

  • 1 January 1979
    • journal article
    • research article
    • Vol. 63  (11-1) , 2009-2010
Abstract
Patients (29) with advanced malignant melanoma were randomized to receive DTIC [5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide] at a dose of 200 mg/m2 i.v. on days 1-5 and cis-dichlorodiammineplatinum(II) at a dose of 40 mg/m2 i.v. on days 1 and 4 repeated every 4 wk (group A) or the same drugs plus procarbazine at a dose of 75 mg/m2 orally daily on days 1-8 and vincristine at a dose of 1.4 mg/m2 i.v. on day 1 (group B). These drugs were generally well-tolerated, but 5 of 16 patients in group A and 6 of 13 patients in group B required dose modification for hematologic or renal toxicity. There were 6 objective responses among 16 patients in group A including 1 complete regression; there were 2 objective responses among 13 patients in group B.